CANF (Can Fite Biopharma) Cyclically Adjusted Book per Share: $67.26 (As of Dec. 2025)


CANF Can Fite Biopharma Ltd CANF
55 GF Score
Price $2.75
GF Value $5.68
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Can Fite Biopharma Cyclically Adjusted Book per Share?

Can Fite Biopharma CANF -6.46% 55 Cyclically Adjusted Book per Share is $67.26 as of Dec. 2025. GuruFocus rates CANF with a GF Score™ of 55/100 and a GF Value™ of $5.68 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Can Fite Biopharma's adjusted book value per share data for the fiscal year that ended in Dec. 2025 was $4.272. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $67.26 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Can Fite Biopharma's average Cyclically Adjusted Book Growth Rate was -46.60% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -30.70% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -17.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Can Fite Biopharma was -2.80% per year. The lowest was -30.70% per year. And the median was -7.95% per year.

As of today (2026-06-27), Can Fite Biopharma's current stock price is $ 2.75. Can Fite Biopharma's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec. 2025 was $67.26. Can Fite Biopharma's Cyclically Adjusted PB Ratio of today is 0.04.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Can Fite Biopharma was 0.69. The lowest was 0.01. And the median was 0.08.


Can Fite Biopharma  (AMEX:CANF) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Can Fite Biopharma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.75/67.26
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Can Fite Biopharma was 0.69. The lowest was 0.01. And the median was 0.08.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Can Fite Biopharma Cyclically Adjusted Book per Share Related Terms


Can Fite Biopharma Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Can Fite Biopharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Can Fite Biopharma Cyclically Adjusted Book per Share Chart

Can Fite Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 764.96 737.48 718.92 538.25 67.26

Can Fite Biopharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 718.92 36.42 538.25 36.35 67.26

CANF vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Can Fite Biopharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Can Fite Biopharma Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Can Fite Biopharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Can Fite Biopharma's Cyclically Adjusted PB Ratio falls into.


CANF
55GF Score
Can Fite Biopharma Ltd CANF
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Can Fite Biopharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Can Fite Biopharma's adjusted Book Value per Share data for the fiscal year that ended in Dec. 2025 was:

Adj_Book=Book Value per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=4.272/324.0540*324.0540
=4.272

Current CPI (Dec. 2025) = 324.0540.

Can Fite Biopharma Annual Data

Book Value per Share CPI Adj_Book
201612 773.000 241.432 1,037.533
201712 835.667 246.524 1,098.478
201812 430.714 251.233 555.558
201912 122.100 256.974 153.973
202012 78.883 260.474 98.138
202112 105.750 278.802 122.914
202212 32.882 296.797 35.902
202312 27.502 306.746 29.054
202412 10.938 315.605 11.231
202512 4.272 324.054 4.272

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $67.26 mean?
Can Fite Biopharma (CANF) has a Cyclically Adjusted Book per Share of $67.26 as of Dec. 2025. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Can Fite Biopharma and its competitors.
Is Can Fite Biopharma's Cyclically Adjusted Book per Share too high?
Can Fite Biopharma's current Cyclically Adjusted Book per Share is $67.26. Overall, Can Fite Biopharma has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Can Fite Biopharma's Cyclically Adjusted Book per Share compare to VRTX and REGN?
Can Fite Biopharma's Cyclically Adjusted Book per Share of $67.26 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Can Fite Biopharma and its competitors. Can Fite Biopharma's current Cyclically Adjusted Book per Share is $67.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Can Fite Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Can Fite Biopharma (CANF) is currently considered Possible Value Trap. The stock's GF Value™ is $5.68, compared to a current price of $2.75 — trading 51.6% below its estimated fair value. The current Cyclically Adjusted Book per Share is $67.26. Can Fite Biopharma's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Can Fite Biopharma (CANF), the current Cyclically Adjusted Book per Share is $67.26 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Can Fite Biopharma (CANF) Overvalued in 2026?

Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued. The current stock price of $2.75 is trading 51.6% below its estimated GF Value™ of $5.68. GuruFocus considers Can Fite Biopharma to be Possible Value Trap.

Key valuation signals for CANF:

  • Cyclically Adjusted Book per Share: $67.26
  • GF Value™: $5.68 vs. price of $2.75 (51.6% below fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Can Fite Biopharma Business Description

Other Exchanges CANF:Israel
Address 26 Ben Gurion Street, Ramat Gan, ISR, 5257346
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
55GF Score

Get the complete analysis for CANF

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.75
Price
$5.68
GF Value